NEW YORK, Jan. 13, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
YogaWorks, Inc. (NasdaqGM: YOGA) Class Period: Pursuant to the IPO commenced around August 10, 2017 and closed on August 16, 2017 Lead Plaintiff Deadline: February 25, 2019
The complaint alleges that Defendants violated their disclosure obligations because the Offering Materials materially misrepresented and failed to adequately disclose the truth concerning several known trends negatively impacting YogaWorks’ business at the time of the IPO, including, inter alia: (i) declining studio profitability; (ii) the impact of increased corporate overhead; (iii) declining financial metrics that would ultimately lead to a substantial impairment charge and (iv) the conditions that led the Defendants to postpone the initial offering.
Get additional information about the YOGA lawsuit: http://www.kleinstocklaw.com/pslra-1/yogawork...orm?wire=3
Immunomedics, Inc. (NASDAQ: IMMU) Class Period: August 23, 2018 to December 20, 2018 Lead Plaintiff Deadline: February 25, 2019
The complaint alleges that, throughout the class period, defendants made false and misleading statements. The United States Food & Drug Administration issued citations against Immunomedics for multiple violations at its Morris Plains, New Jersey facility. The FDA citations included the manipulation of bioburden samples, backdating of records, and misrepresentation of integrity test procedures. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. On December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity Breach.” Upon this news, Immunomedics’ stock price fell sharply, damaging investors.
Get additional information about the IMMU lawsuit: http://www.kleinstocklaw.com/pslra-1/immunome...orm?wire=3
DXC Technology Company (NYSE: DXC) Class Period: February 8, 2018 to November 6, 2018 Lead Plaintiff Deadline: February 25, 2019
The lawsuit alleges DXC Technology Company made materially false and/or misleading statements and/or failed to disclose during the class period that: (a) the Company had changed or planned to change the operations of its sales teams, deploying generalized sales teams as opposed to the specialized teams that were better capable of delivering specialized services to its clients; (b) the Company’s workforce optimization strategy of sharply reducing staff while reducing costs was resulting in a shortage of sales personnel who could execute on demand for services, thereby risking and ultimately losing sales and revenue opportunities; (c) in light of the above, the Company’s revenue and financial performance guidance for the fiscal year 2019 and its reaffirmation of the guidance during the Class Period was without a reasonable basis.
Get additional information about the DXC lawsuit: http://www.kleinstocklaw.com/pslra-1/dxc-tech...orm?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: J. Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
